资讯

ascopubs.org

Identifying Patients With Low Relapse Rate Despite High-Risk Estrogen Receptor–Positive ...

US Food and Drug Administration Approval Summary: Inavolisib With Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA-Mutated, Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor ...